Arbele

07/07/2025

Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition
https://www.prnewswire.com/news-releases/arbele-wins-top-prize-at-bcics-4th-annual-biomedical-pitch-competition-302496632.htmlArbele

04/02/2025

Arbele is a clinical stage biotech centred on an innovative T-Cell Engager approach to gastrointestinal cancers. Chairman and founder John Luk explains the prevalence of these cancers in China, the company’s challenging clinical trials journey, and the pursuit of breakthrough and fast-track design...

12/10/2024

Arbele collaborates with BioAI and Chime Biologics to accelerate AI-powered cancer therapies and companion diagnostics.

26/04/2024

/PRNewswire/ -- Arbele, a clinical-stage biotechnology company focused on the development of novel immunotherapies targeted for advanced gastrointestinal...

02/08/2023

https://www.prnewswire.com/news-releases/arbele-announces-early-safety-data-for-novel-cdh17xcd3-bispecific-t-cell-engager-at-american-society-of-clinical-oncology-breakthrough-meeting-301891273.html

/PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early...

01/08/2023

ASCO Breakthrough Yokohama, Japan 2023 Abstracts Now Available Online
Phase 1A, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3, in advanced gastrointestinal malignancies expressing CDH17.

Department of Medicine, Queen Mary Hospital, Hong Kong, China, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China, Arbele Corporation, Bellevue, WA, Arbele Pty Ltd, Sydney, NSW, Australia, University of Sydney Medical School, Sydney, NSW, Australia

29/06/2023

In observance of , we applaud the extraordinary advancements accomplished by globally in the pursuit of novel cancer treatment options. , which harnesses the inherent power of the body's immune system to selectively target and eliminate cells, stands at the forefront of this transformative work.

To exemplify impactful research and innovation, we're throwing back to last year's Global Summit, where Arbele CEO, John Luk, took the stage to share remarkable progress in their immunotherapeutic platforms to accelerate the development of “first-in-class” antibody-based biologics to treat GI cancers.

Stay tuned for upcoming details for this year's Global Summit!

09/06/2023

See you next year in San Diego. Thanks for all the advices and opportunities!

03/06/2023

05/05/2023

At TibTech, we are focused on developing advanced in vitro diagnostic assays to detect, diagnose and monitor gastrointestinal cancers. We work closely with our…

05/05/2023

/PRNewswire/ -- Arbele, a biotechnology company dedicated to fighting gastrointestinal cancers, celebrates its 7th anniversary and the opening of Tiberias...

03/05/2023

https://www.linkedin.com/feed/update/urn:li:activity:7057564907914866688